1.45
-0.08 (-5.23%)
| Previous Close | 1.53 |
| Open | 1.53 |
| Volume | 84,889 |
| Avg. Volume (3M) | 193,864 |
| Market Cap | 54,339,612 |
| Price / Earnings (Forward) | 28.65 |
| Price / Book | 44.71 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -0.110 |
| Total Debt/Equity (MRQ) | 6.71% |
| Current Ratio (MRQ) | 1.91 |
| Operating Cash Flow (TTM) | -4.91 M |
| Levered Free Cash Flow (TTM) | -3.52 M |
| Return on Assets (TTM) | -99.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Jupiter Neurosciences, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 0.5 |
| Average | 0.50 |
|
Jupiter Neurosciences Inc is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to most central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 57.50% |
| % Held by Institutions | 1.17% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |